These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29219657)

  • 1. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
    Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
    Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
    Dent P; Booth L; Poklepovic A; Kirkwood JM
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib augments the lethality of [regorafenib + sildenafil].
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
    J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
    Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
    Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
    Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L; Poklepovic A; Dent P
    Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.
    Booth L; Roberts JL; Rais R; Kirkwood J; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Oncotarget; 2018 Jan; 9(5):6062-6074. PubMed ID: 29464055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
    Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
    Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
    Booth L; Poklepovic A; Hancock JF; Dent P
    Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
    Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
    J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.